Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.
Roche Holding AG Akt 0.65% CHF232.25B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback